Trial Profile

A Long-term Follow-Up Study to Evaluate the Safety and Efficacy of RGX-314 Following Subretinal Administration in Participants With Neovascular Age-related Macular Degeneration and Fellow Eye Treatment Substudy

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 24 May 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

29 Mar 2023 According to ClinicalTrials.gov record, protocol has been amended to increase patient number from 42 to 865, treatment arm changed from 1 to 2. Official title is changed and so the age criteria from 18 years to 50 years. Study design is now Single Group Assignment and addition of new primary endpoint.
29 Mar 2023 Planned number of patients changed from 42 to 865.
29 Mar 2023 Planned End Date changed from 1 Jun 2024 to 1 Dec 2028.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com